{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17","upperLimit":"37.3","value":"26.3"},{"groupId":"OG001","lowerLimit":"4.7","upperLimit":"21.9","value":"11.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1;","dispersionType":"95% Confidence Interval","groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"OG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"OG001","title":"Investigator Chosen Chemotherapy"}],"paramType":"NUMBER","populationDescription":"The PD-L1 positive population is defined as a visually-estimated combined positive score (vCPS) ≥10%","reportingStatus":"POSTED","timeFrame":"Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)","title":"Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}